These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2220661)

  • 1. A phase II trial of mitomycin in patients with epithelial ovarian carcinoma resistant to cisplatin or carboplatin.
    Hoskins PJ; McMurtrie E; Swenerton KD
    Am J Clin Oncol; 1990 Oct; 13(5):416-9. PubMed ID: 2220661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
    Lund B; Hansen OP; Hansen HH; Hansen M
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined carboplatin plus ifosfamide and cisplatin in patients with advanced ovarian carcinoma. A phase I-II study. GOCS (Gynecological Oncology Cooperative Study).
    Lorusso V; Leone B; Di Vagno G; Manzione L; Palmeri S; Vallejo C; Machiavelli M; Nacci G; Bilancia D; Leonardi V; Catino A; Gargano G; Loverro G; Selvaggi L; De Lena M
    Gynecol Oncol; 1998 Feb; 68(2):172-7. PubMed ID: 9514802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer.
    Taylor AE; Wiltshaw E; Gore ME; Fryatt I; Fisher C
    J Clin Oncol; 1994 Oct; 12(10):2066-70. PubMed ID: 7931475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study.
    Weiss G; Green S; Alberts DS; Thigpen JT; Hines HE; Hanson K; Pierce HI; Baker LH; Goodwin JW
    Eur J Cancer; 1991; 27(2):135-8. PubMed ID: 1827275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitomycin is active against refractory germ-cell tumors. A phase II study.
    Hoskins P; Coppin CM; Murray N
    Am J Clin Oncol; 1990 Feb; 13(1):35-8. PubMed ID: 2154922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin.
    Mangioni C; Bolis G; Pecorelli S; Bragman K; Epis A; Favalli G; Gambino A; Landoni F; Presti M; Torri W
    J Natl Cancer Inst; 1989 Oct; 81(19):1464-71. PubMed ID: 2674459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma.
    Evans BD; Raju KS; Calvert AH; Harland SJ; Wiltshaw E
    Cancer Treat Rep; 1983 Nov; 67(11):997-1000. PubMed ID: 6315233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease.
    Lund B; Hansen M; Hansen OP; Hansen HH
    J Clin Oncol; 1989 Oct; 7(10):1469-73. PubMed ID: 2674334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose platinum chemotherapy in advanced ovarian cancer: a phase II study.
    Bertelsen K; Bastholt L
    Gynecol Oncol; 1992 Jan; 44(1):79-82. PubMed ID: 1730430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of activity of 5-fluorouracil plus mitomycin-C as salvage therapy in cisplatin-resistant epithelial ovarian cancer: results of a phase II trial.
    Hempling RE; Piver MS; Baker TR; O'Neill Mullen C
    Eur J Gynaecol Oncol; 1994; 15(3):165-9. PubMed ID: 7957319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
    Bookman MA; Malmström H; Bolis G; Gordon A; Lissoni A; Krebs JB; Fields SZ
    J Clin Oncol; 1998 Oct; 16(10):3345-52. PubMed ID: 9779711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous infusion of 5-fluorouracil in ovarian cancer patients refractory to cisplatin and carboplatin.
    de Graeff A; van Hoef ME; Tjia P; Heintz AP; Neijt JP
    Ann Oncol; 1991 Oct; 2(9):691-2. PubMed ID: 1742226
    [No Abstract]   [Full Text] [Related]  

  • 15. Intraperitoneal carboplatin: rationale and experience.
    Speyer JL; Sorich J
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):107-13. PubMed ID: 1411621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy.
    Speyer JL; Beller U; Colombo N; Sorich J; Wernz JC; Hochster H; Green M; Porges R; Muggia FM; Canetta R
    J Clin Oncol; 1990 Aug; 8(8):1335-41. PubMed ID: 2199620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin/carboplatin therapy in non-small cell lung cancer.
    Niitani H; Kobayashi K
    Oncology; 1992; 49 Suppl 1():51-6. PubMed ID: 1323812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study.
    Lambert HE; Rustin GJ; Gregory WM; Nelstrop AE
    Ann Oncol; 1997 Apr; 8(4):327-33. PubMed ID: 9209661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients.
    Colombo N; Speyer JL; Green M; Canetta R; Beller U; Wernz JC; Meyers M; Widman T; Blum RH; Piccart M
    Cancer Chemother Pharmacol; 1989; 23(5):323-8. PubMed ID: 2650904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.